Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Barr Kicks Off Enjuvia Detailing Two Years After First Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Subsidiary Duramed will support the estrogen therapy launch with 250 sales reps.

You may also be interested in...

Barr’s Bijuva Estrogen Cream Is “Not Approvable” At FDA

The agency will require additional clinical evidence pertaining to an unmet endpoint, Barr says. Two of three endpoints for the synthetic conjugated estrogens cream were met during clinical studies; the third was modified at FDA’s guidance after the trials began, the company says.

Barr Enjuvia Hormone Therapy To Launch After Approval Of More Doses

Barr plans to launch Enjuvia by early 2005 when three additional strengths of the hormone therapy product are expected to become available, the company said

Biohaven Shoots For Oral CGRP Leadership As Nurtec ODT Gains Momentum

The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts